GlassScriptPhysician profile
Setu Nikhil Patel
NPI 1801259361
$14,054.66
in general payments reported to CMS, 2019-2025
20 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $241 · 2021: $757 · 2022: $1,047 · 2023: $9,362 · 2024: $2,132 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,847 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Consulting Fee: $1,375 · Travel and Lodging: $1,247 · Education: $40.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,847.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Consulting Fee | $1,375.00 |
| Travel and Lodging | $1,246.97 |
| Education | $40.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,896.56 | 2022-2025 | Clareon Panoptix Pro, Unity |
| Alimera Sciences, INC. | $3,668.03 | 2021-2024 | Iluvien, Yutiq |
| Regeneron Pharmaceuticals, INC. | $1,375.00 | 2023 | Eylea |
| Regeneron Healthcare Solutions, INC. | $819.74 | 2020-2025 | Eylea Hd, Eylea |
| Eyepoint US, INC. | $508.57 | 2020-2023 | |
| Bausch & Lomb Americas INC. | $350.91 | 2024 | Stellaris Elite, Stellaris |
| Allergan, INC. | $285.07 | 2020-2021 | |
| Dutch Ophthalmic, USA | $270.62 | 2022-2024 | Tissueblue, Eva, Combined Machine |
| Glaukos Corporation | $204.84 | 2024-2025 | Idosetr, Idose |
| Abbvie INC. | $171.41 | 2022-2025 | |
| Astellas Pharma US INC | $94.96 | 2023-2025 | Izervay |
| Genentech, INC. | $93.75 | 2025 | Vabysmo |
| Harrow Eye, LLC | $89.89 | 2025 | Triesence, Iheezo |
| Genentech USA, INC. | $65.59 | 2020-2023 | Vabysmo |
| Carl Zeiss Meditec USA, INC. | $51.79 | 2023 | Artevo 800 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $29.23 | 2023 | |
| Apellis Pharmaceuticals, INC. | $23.08 | 2024 | Syfovre |
| Novartis Pharmaceuticals Corporation | $21.26 | 2021 | |
| Ani Pharmaceuticals, INC. | $18.07 | 2025 | Purified Cortrophin Gel |
| Rhythm Pharmaceuticals, INC. | $16.29 | 2023 | Imcivree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Setu Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.